FC
PTGX icon

FORA Capital’s Protagonist Therapeutics PTGX Stock Holding History

FORA Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,130
Closed -$788K – 572
2025
Q4 		$788K Buy
9,130
+5,445
+148% +$446K 0.1% 241
2025
Q3 		$245K Buy
+3,685
New +$209K 0.04% 411
2021
Q3 		– Sell
-2,731
Closed -$123K – 742
2021
Q2 		$123K Buy
+2,731
New +$90.1K 0.02% 549
2020
Q3 		– Sell
-11,288
Closed -$199K – 917
2020
Q2 		$199K Buy
+11,288
New +$142K 0.07% 344

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

FORA Capital's PTGX Position: Q1 2026 in Review

FORA Capital sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 9,130 shares — an estimated $788K sold.

FORA Capital first reported a position in PTGX in Q2 2020 and held it in 4 quarters. The position peaked at $788K in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • FORA Capital reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • FORA Capital sold 9,130 Protagonist Therapeutics shares in Q1 2026, an estimated $788K.
  • FORA Capital first reported a position in Protagonist Therapeutics in Q2 2020 and held it in 4 quarters.
  • FORA Capital's Protagonist Therapeutics position peaked at $788K in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.